The US Food and Drug Administration has given pre-marketing approval for ExAblate targeted focused ultrasound treatment from Israel’s InSightec Image Guided Treatment Ltd.. The approval is initially for bone cancer patients who cannot undergo radiation therapy.
http://www.globes.co.il/serveen/globes/docview.asp?did=1000791836&fid=1725